|
|
|
|
Office Locations:
|
1 Letterman Drive
San Francisco, CA 94129
Phone: 415-441-1460
| |
|
|
|
|
|
|
Information Technology
Life Sciences & Healthcare
Media & Digital Media
Software & Internet
|
|
|
|
Maverick Capital is a global investment firm with offices in New York, San Francisco, London, Hong Kong, Philadelphia and Dallas. Maverick's investment team seeks to grow and preserve capital for its investors, primarily through a long/short hedged equity strategy. Since the Firm's inception in 1993, Maverick has strategically invested in private companies that represent disruptive business models or technologies. Maverick actively partners with portfolio company teams through the deployment of its resources and deep fundamental research capabilities to help entrepreneurs build their businesses.
|
|
|
|
|
|
|
Investment Firm Key
VC = Venture Capital
PE = Private Equity
A = Angel
I = Incubator
MB = Merchant Bank
VD = Venture Debt
FI = Family Investment Office
FOF = Fund of Funds
ED = Economic Development Office
TT = Technology Transfer Office
CVC = Corporate Venture Capital
SEC = Secondary Purchaser
HF = Hedge Fund/Mutual Fund
|
|
| COMPANY STAGE | REVENUE |
| Venture Capital | |
Seed Stage
(includes "pre-seed," or
concept stage) | No Revenue |
| Early Stage | Minimal
Revenue |
Growth Stage
(also called Mid-stage) | $2M-$7M |
Expansion Stage
(also called Late-stage) | $7M and greater |
| Private Equity | |
| Lower Middle Market | $10M-$249M |
| Middle Market | $250M-$499M |
| Upper Middle Market | $500M-$1B |
| Large Cap | >$1B |
|
|
|
|
|
|
|
| Name | |
| |
Title | |
|
| Alex S. Rafal | |
| |
Managing Director and Security Analyst | |
| Brett Caughran | |
| |
Senior Analyst | |
| Corrie Mattorano | |
| |
| |
| Eric Kim | |
| |
Managing Director | |
| Evan Acton Wyly | |
| |
Managing Partner | |
|
|
|
|
Date
|
Name
|
State
|
Amount
|
Stage
|
10/18/2024
|
Terray Therapeutics
|
CA
|
$120,000,000
|
Series B
|
10/09/2024
|
TensorWave
|
NV
|
$43,000,000
|
SAFE
|
04/29/2024
|
Thintronics
|
CA
|
$23,000,000
|
Series A
|
04/10/2024
|
Auradine
|
CA
|
$80,000,000
|
Series B
|
04/04/2024
|
SiMa.ai
|
CA
|
$70,000,000
|
Venture
|
02/13/2024
|
Areteia Therapeutics
|
NC
|
$75,000,000
|
Series A
|
|
|
|
|
|
|
|
